Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily ...

CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced strong financial results for the third ...